Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (251-260 of 320) with videos related to

Pageof 32
Sort By:
The American Journal of Pathology|July 19, 2011
Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcomeDorian R A Swarts, Sandra M H Claessen, Yvonne M H Jonkers, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2022
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label studyDaniel S W Tan, Sang-We Kim, Santiago Ponce Aix, et al.
Cancer Discovery|February 19, 2014
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancerElza C de Bruin, Catherine Cowell, Patricia H Warne, et al.
Cell Reports|July 5, 2016
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsEkaterina A Semenova, Min-Chul Kwon, Kim Monkhorst, et al.
Oncotarget|November 7, 2015
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancerR Jonas A Nilsson, Niki Karachaliou, Jordi Berenguer, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2015
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysisJustine L Kuiper, Lizza E Hendriks, Anthonie J van der Wekken, et al.
Plos One|May 16, 2018
The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trialGitta Kleijn, Birgit I Lissenberg-Witte, Ernst T Bohlmeijer, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJames Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
British Journal of Cancer|July 25, 2019
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 studyHarry J M Groen, Erik H F M van der Heijden, Theo J Klinkenberg, et al.
Pageof 32

Showing results (251-260 of 320) with videos related to

Sort By:
Pageof 32
The American Journal of Pathology|July 19, 2011
Deletions of 11q22.3-q25 are associated with atypical lung carcinoids and poor clinical outcomeDorian R A Swarts, Sandra M H Claessen, Yvonne M H Jonkers, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2022
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label studyDaniel S W Tan, Sang-We Kim, Santiago Ponce Aix, et al.
Cancer Discovery|February 19, 2014
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancerElza C de Bruin, Catherine Cowell, Patricia H Warne, et al.
Cell Reports|July 5, 2016
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in PatientsEkaterina A Semenova, Min-Chul Kwon, Kim Monkhorst, et al.
Oncotarget|November 7, 2015
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancerR Jonas A Nilsson, Niki Karachaliou, Jordi Berenguer, et al.
Lung Cancer (Amsterdam, Netherlands)|June 29, 2015
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysisJustine L Kuiper, Lizza E Hendriks, Anthonie J van der Wekken, et al.
Plos One|May 16, 2018
The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trialGitta Kleijn, Birgit I Lissenberg-Witte, Ernst T Bohlmeijer, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJames Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
British Journal of Cancer|July 25, 2019
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 studyHarry J M Groen, Erik H F M van der Heijden, Theo J Klinkenberg, et al.
Pageof 32